Vanda wins FDA approval for motion sickness drug news2025-12-31T15:47:05+00:00December 31st, 2025|Endpoints News|
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndromenews2025-12-31T15:20:26+00:00December 31st, 2025|Endpoints News|
Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective datenews2025-12-29T21:20:03+00:00December 29th, 2025|Endpoints News|
Genmab terminates Phase 3 lung cancer asset that BioNTech ditchednews2025-12-29T15:17:58+00:00December 29th, 2025|Endpoints News|
CMS unveils Medicare coverage model for weight loss drugsnews2025-12-26T18:31:31+00:00December 26th, 2025|Endpoints News|
Biohaven’s ion channel drug fails again, this time in major depressive disordernews2025-12-26T16:12:39+00:00December 26th, 2025|Endpoints News|
Agios finally wins approval for Aqvesme in thalassemianews2025-12-24T13:03:04+00:00December 24th, 2025|Endpoints News|
Drugmakers with White House pricing deals may skirt new Medicare demosnews2025-12-23T18:57:02+00:00December 23rd, 2025|Endpoints News|
Novo Nordisk eyes a strong launch with FDA approval of obesity pillnews2025-12-22T23:54:53+00:00December 22nd, 2025|Endpoints News|
CMS proposes two long-awaited Medicare drug pricing demosnews2025-12-22T19:16:42+00:00December 22nd, 2025|Endpoints News|
